Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Vishee Medical Technology Co (SHSE:688580) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nanjing Vishee Medical Technology Co EBITDA Margin % Related Terms
Nanjing Vishee Medical Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vishee Medical Technology Co EBITDA Margin % Chart
SHSE:688580 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Nanjing Vishee Medical Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Vishee Medical Technology Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Vishee Medical Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nanjing Vishee Medical Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vishee Medical Technology Co (SHSE:688580) has a EBITDA Margin % of 66.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Vishee Medical Technology Co and its competitors. This is 75% above median its historical median of 37.89. Over the past decade, Nanjing Vishee Medical Technology Co's EBITDA Margin % has ranged from 19.77 to 48.52. According to the industry distribution chart, Nanjing Vishee Medical Technology Co ranks #33 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 4%.
Is Nanjing Vishee Medical Technology Co's EBITDA Margin % too high?
Nanjing Vishee Medical Technology Co's current EBITDA Margin % of 66.36% is 75% above median its 10-year median of 37.89. Over the past 10 years, this metric has ranged from a low of 19.77 to a high of 48.52. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Nanjing Vishee Medical Technology Co's value of 66.36% is 788.4% above this industry median. Based on the distribution chart, Nanjing Vishee Medical Technology Co ranks #33 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanjing Vishee Medical Technology Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vishee Medical Technology Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Vishee Medical Technology Co ranks #33 out of 815 companies for EBITDA Margin %. This places Nanjing Vishee Medical Technology Co in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Nanjing Vishee Medical Technology Co's value of 66.36% is 788.4% above this benchmark. Historically, Nanjing Vishee Medical Technology Co's own EBITDA Margin % has ranged from 19.77 to 48.52 over the past decade. While the company's 10-year median is 37.89 vs. the industry median of 7.47, Nanjing Vishee Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Vishee Medical Technology Co's current EBITDA Margin % of 66.36% is 788.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Vishee Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Vishee Medical Technology Co's current EBITDA Margin % is 66.36%, which is 75% above median its own 10-year median of 37.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vishee Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co (SHSE:688580) is currently considered Fairly Valued. The stock's GF Value™ is ¥54.15, compared to a current price of ¥50.56 — trading 6.6% below its estimated fair value. The current EBITDA Margin % is 66.36%, which is 75% above median its 10-year median of 37.89 and 788.4% above the Medical Devices & Instruments industry median of 7.47. Nanjing Vishee Medical Technology Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nanjing Vishee Medical Technology Co (SHSE:688580), the current EBITDA Margin % is 66.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vishee Medical Technology Co (SHSE:688580) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co stock appears to be undervalued.
The current stock price of ¥50.56 is trading 6.6% below its estimated GF Value™ of ¥54.15.
GuruFocus considers Nanjing Vishee Medical Technology Co to be Fairly Valued.
Key valuation signals for SHSE:688580:
EBITDA Margin %: 66.36% (75% above median its 10-year median of 37.89)
GF Value™: ¥54.15 vs. price of ¥50.56 (6.6% below fair value)
Industry Position: 788.4% above the Medical Devices & Instruments median (#33 of 815)
No single metric tells the full story. See the SHSE:688580 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Vishee Medical Technology Co Business Description
Nanjing Vishee Medical Technology Co Ltd is engaged in production and sales of rehabilitation medical devices. The company's products under Pelvic floor and postpartum rehabilitation include Pelvic floor electromyography biofeedback instrument; Myotrac series biological stimulation feedback instrument; Ruiyi Series Biostimulation Feedback Apparatus; Magneuro Series Magnetic Stimulator; Female psychological rehabilitation; Neonatal electroencephalograph; Consumables; and under Mental rehabilitation include Multi-parameter biofeedback instrument; Group biofeedback; Magneuro Series Magnetic Stimulator; and Cognitive dysfunction treatment software.
89GF Score
Get the complete analysis for SHSE:688580
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688580 has been successfully added to your 
